Transcranial magnetic stimulation: a new tool in the fight against depression by Grunhaus, Leon et al.
ranscranial magnetic stimulation (TMS) was
introduced by Barker in 1985
1 as a tool for noninva-
sively stimulating the central nervous system (CNS).
The first experiments by Barker et al were aimed at
inducing motor movements and measuring nerve con-
duction. These authors based their studies on previ-
ous reports that electromagnetic coils placed near the
human head can give rise to neurological phenomena
such as phosphenes and vertigo, and cause some to
feel faint.
2
The dramatic implications of this initial demonstration
by Barker et al are becoming apparent with the expo-
nential increase in the number of studies that use TMS
as a tool for exploring CNS function in normal indi-
viduals and in disease.
3,4
TMS is based on Faraday’s principle of mutual induc-
tion, which states that electrical energy can be con-
verted into magnetic energy, and vice versa. During
TMS, a bank of capacitors repeatedly and rapidly dis-
charges into an electric coil and produces a time-
varying magnetic pulse. If the coil is placed near the
head of a human or animal, the magnetic field pene-
trates unimpeded into the brain and induces an elec-
tric field in the underlying region of the cerebral cor-
tex. This electric field in turn produces a charge
across the excitable neuronal membranes and, if it is
of sufficient intensity, induces neuronal depolariza-
tion and an action potential.The propagation of this
action potential along nerve structures and neuronal
networks constitutes the neuronal basis for TMS
actions.
4 TMS has both local effects, by stimulation
of interneurons, and distant effects through stimula-
tion of axonal connections. The magnetic field
induced during TMS declines logarithmically with
distance from the coil. In humans, this limits the
effects of TMS to cortical depolarization (about 2 cm
below the skull).
5 It is possible that improvements in
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Since its introduction to the clinical realm in 1985, trans-
cranial magnetic stimulation (TMS) has rapidly devel-
oped into a tool for exploring central nervous system
function in both health and disease. The antidepressant
effects of TMS were initially observed in 1993. Since
then, a solid body of evidence has accumulated suggest-
ing antidepressant effects for both slow TMS (sTMS) and
repetitive TMS (rTMS). This review is divided into four
parts. First, it addresses the basic concepts governing
TMS, and then, second, it discusses the technical para-
meters involved in administering TMS. Knowledge of
these parameters is necessary for understanding how
TMS is administered, and how manipulation of the tech-
nique impacts on the results obtained. Third, we review
the most relevant studies on the antidepressant effects
of sTMS and rTMS published to date. Finally, we discuss
cortical excitability and how the understanding of this
basic neurophysiological function of cortical neurons can
be used for monitoring the effects of TMS. In our discus-
sion, we conclude that the time has arrived for TMS to
be offered to depressed patients as a treatment. 
Dialogues Clin Neurosci. 2002;4:93-103.the manufacturing of coils will allow the delivery of
magnetic pulses to deeper brain areas.
Effects similar to those of TMS can be obtained with
electrical pulses (transcranial electrical stimulation);
however,the impedance of the tissue requires the elec-
trical charge administered to be large, and this stimu-
lation is usually painful and disturbing for patients.In
TMS,the magnetic pulse crosses the scalp almost pain-
lessly.
4
The study of the effects of TMS received a significant
boost with the introduction of stimulators with more
powerful capacitors that allowed the delivery of mag-
netic pulses at frequencies of up to 100 Hz. It is con-
ventional to refer to pulses of 1 Hz or less as slow TMS
(sTMS),and pulses of above 1 Hz as repetitive (or fast)
TMS (rTMS). In humans, the risk of induction of
seizures has limited the frequency of rTMS to a maxi-
mum of 25 Hz.
6,7 The only exception to this was the
study of Lisanby et al
8 in which stimulations of 
40 Hz were used during research into magnetically
induced seizures.
TMS is a rapidly evolving technique with many appli-
cations in psychiatry, neurology, cognitive neuro-
sciences, and basic neurosciences. In this review, we
will focus on the importance of TMS as a tool in the
treatment of depressive illness. We will discuss the
relevant technical aspects of TMS, which are essen-
tial for understanding the effects of this treatment
modality, and we will conclude with an update on the
electrophysiological mechanisms of the action of TMS
that are relevant for understanding its effects in
depression.
The technique of TMS
In TMS, the patient does not require special prepara-
tions besides the standard psychiatric and medical
workup for depressive illness. It is important to follow
the safety guidelines, and exclusion criteria have been
produced by Lorberbaum and Wassermann
6 and Wasser-
mann
7 for the safe administration of TMS.The main lim-
itations of TMS relate to the presence of active neuro-
logical illness,or to the presence of metallic inserts in the
body, particularly in the head.Although TMS has been
administered during pregnancy,
9 it is considered to be a
relative contraindication for TMS.The technical consid-
erations for TMS are listed in Table I.
Magnetic motor threshold and 
the power of stimulation
Magnetic motor threshold (MT) is defined as the mini-
mal amount of machine power needed to induce a
deflection of 50 µV in the electromyographic record-
ings in 5 out of 10 trials.
10 It has been argued that the dif-
ference between the MT (ie,electromyographic record-
ing of motor evoked potentials [MEP]) and the twitch
threshold (ie, hand movement that corresponds to the
MEP) is minimal and probably clinically irrelevant.
11
However, current safety guidelines require monitoring
by electromyography (EMG) for identification of after-
discharges or spreads of excitation, ie, the established
forerunners of seizures.
12
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Selected abbreviations and acronyms
ECT electroconvulsive therapy
EMG electromyography
GAF global assessment of function (scale)
HRSD Hamilton Rating Scale for Depression
LDLPFC left dorsolateral prefrontal cortex
MEP motor evoked potential
MT motor threshold
RDLPFC right dorsolateral prefrontal cortex
rTMS repetitive (or fast) transcranial magnetic stimulation
sTMS slow transcranial magnetic stimulation 
TMS transcranial magnetic stimulation
Table I. Relevant technical issues in the administration of transcranial mag-
netic stimulation (TMS). sTMS, slow TMS; rTMS, repetitive TMS.
Motor threshold
Scalp-to-cortex distance
Subthreshold vs threshold or suprathreshold stimulations
Types of coil
Round coil
Figure-of-eight coil
Coil placement
Anatomical landmarks vs neuronavigation
Frequency of stimulation
sTMS vs rTMS
Total number of magnetic pulses administered 
Per session
Per course of TMS
Total number of treatments per courseIn sTMS,magnetic stimulations are usually administered
at 100% machine power, whereas in rTMS the power
ranges between 80% and 120% MT (usually about 40%
to 70% of the stimulator’s maximum). Initial studies
with rTMS were performed with the power set at 80%
to 90% MT.However,more recent studies generally use
around 100% to 110% MT. Stimulation paradigms sig-
nificantly above MT have been reported to be associ-
ated with the induction of seizures,
7 or have been used to
induce seizures in a controlled setting.
8 It is important to
note that,since the introduction of the safety guidelines
for the administration of TMS, there has been no new
report of seizures during TMS.
13
MT may not be the best guiding principle for setting the
power of stimulation when rTMS is performed over the
frontal cortex. Indeed, what is appropriate for the motor
cortex may not be appropriate for the frontal or prefrontal
cortex. Kozel et al
14 and McConnell et al
15 pioneered the
concept that the power of stimulation needs to be calcu-
lated on the basis of the scalp-to-cortex distance and not just
as a function of MT. MT reflects more closely the scalp-
to–motor cortex distance than the scalp-to–prefrontal cor-
tex distance.In elderly patients in whom the scalp-to–frontal
cortex is increased due to brain atrophy,calculations of the
power of stimulation on the basis of scalp-to–motor cortex
distance may underestimate the power needed to stimu-
late the frontal cortex in these individuals.
Coil used for administering TMS
Two main types of coil are used in TMS:the round coil and
the figure-of-eight coil. It is unclear whether one is supe-
rior to the other, as positive results have been reported
with both types.The round coil is more common in single-
pulse and sTMS studies, while the figure-of-eight coil is
used more commonly in rTMS studies.The magnetic field
produced by the round coil is strongest around the perime-
ter of the coil and, therefore, it stimulates a larger but
more diffuse cortical area.The magnetic field of the figure-
of-eight-coil is concentrated over the area where the wings
of the coil meet,providing a much more focused stimula-
tion over a smaller area of the cortex.
5
Coil placement
During TMS, small areas of the brain are stimulated
locally under the coil and distally through axonal con-
nections. Thus, TMS allows the study of both local and
distal effects of magnetic stimulation.
16The importance of
specific brain areas and neuronal networks can be stud-
ied with TMS.In depression,studies have reported ben-
eficial effects with rTMS when the coil is placed over the
left dorsolateral prefrontal cortex (LDLPFC), and with
sTMS when the coil is placed over the right dorsolateral
prefrontal cortex (RDLPFC).
5 In studies with rTMS over
the LDLPFC, the site for stimulation is located by plac-
ing the coil 5 cm rostrally and parasagitally to the motor
cortex. This may not be accurate enough as individual
variations in the anatomy of the cortex are not taken
into account. The method of neuronavigation, which is
commonly used in neurosurgery,relies on magnetic res-
onance imaging (MRI) and frameless stereotaxy to
determine coil placement. This method improves the
ability to target the LDLPFC accurately.
17,18
Frequency of stimulation and total
number of pulses administered per treatment
Magnetic stimulation can be administered at frequen-
cies ranging between less than 1 Hz and 100 Hz. In
humans, there are no safety guidelines for stimulation
above 20 Hz. The remarkable flexibility of this para-
meter may have far-reaching implications for the mag-
netic stimulation of the brain.It has been proposed and
demonstrated that low-frequency stimulation of the
motor cortex leads to brief inhibition of motor
responses,
19 while higher frequency stimulation of the
motor cortex leads to brief excitation of motor
responses.
20 The total number of pulses administered
during a treatment depends on the frequency of stimu-
lation and the length of each treatment. Initial studies
administered few magnetic pulses.More recent studies
introduced the concept of trains of stimulation and also
proposed that additional clinical benefits, especially in
depressive illness, are obtained when the number of
magnetic pulses is increased dramatically.For example,
in previous communications from our laboratory, we
have administered up to 24 000 stimulations per course
of TMS; in an ongoing study, we are testing whether
160 000 stimulations per course would be more effective
in the treatment of severe depression.
Number of treatments
The number of treatments has also varied greatly
between the studies.The initial reports were based on a
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between 5 and 20 treatment days.The relevance of this
difference remains to be established. We recently fin-
ished a study comparing the changes in depression rat-
ings after 2 or 4 weeks of rTMS. Significant additional
clinical gains were noted after 4 weeks (Grunhaus et al,
unpublished data).
Use of sham controls
Open studies with TMS are difficult to evaluate, espe-
cially because of the placebo-like effects that treatment
with magnets may have.However,it is difficult to mask
the effects of the magnet. Two ways to cope with this
problem have been considered: one is the use of sham-
masked stimulations, and the other is the use of a sham
coil.There has been considerable argument on whether
a “true”sham or masked TMS exists.The one-wing,two-
wing, 45-degree, and 90-degree positions have been
explored and have nevertheless been found to induce a
modest amount of magnetic field in the cortex.
21The use
of sham coils seems to be the preferred method
(Neotonus,Marietta,Ga,USA),though there have been
no published research using this coil.
Side effects associated with TMS and rTMS
Overall, TMS and rTMS have so far been remarkably
safe. Initial concerns about the possibility of the induc-
tion of seizures have been allayed since the introduc-
tion of the guidelines for the safe administration of TMS.
Additional concerns like headaches, cognitive effects,
effects of irradiation,and local facial or scalp pain during
the administration of TMS are rare.
7
TMS studies in depression
Following the observations that TMS could provoke
transient mood elevations or acute crying in normal vol-
unteers,
22,23 several researchers described the antide-
pressant effects of single-pulse TMS in small sample of
patients with major depression.
24-28
Hoflich and collaborators from Germany published the
first report on the antidepressant effects of TMS.
27These
authors treated two patients with delusional major
depressive disorder (MDD) with 10 sessions of TMS
(14-mm round coil,250 stimulations at 0.3 Hz per day,at
the vertex, and at 5% to 30% above MT) and followed
these treatments with 10 sessions of electroconvulsive
therapy (ECT). ECT was superior to TMS in both
patients; however, a mild antidepressant effect of TMS
was observed in one of the patients. Additional sTMS
studies are those of Kolbinger et al,
28 Grisaru et al,
26
Conca et al,
24 and Geller et al.
25 These studies were all
performed with round coils,at relatively low frequencies,
and with coil locations at either the vertex or the
LDLPFC. The antidepressant effects of TMS in these
studies were very modest.
Conca et al
24 compared the effects of TMS as an add-on
treatment to ongoing antidepressant medication in
patients with MDD without delusions.The authors ran-
domly assigned patients to one of two groups, one
treated with sTMS and medication, and the other with
medication alone. TMS was administered over several
cortical regions with a round coil.The authors found a
greater remission of depressive symptoms in the sTMS
group after just three sTMS sessions;this difference was
even more significant by the end of the 10th and final
sTMS session. Conca et al repeated this design in a fol-
low-up study of 12 MDD patients without delusions.
29
These authors administered 500 pulses a day for up to 10
days at maximal machine output, and over several cor-
tical regions. They reported a significant response rate
for sTMS-treated patients.
The most comprehensive study with sTMS published so
far is by Klein et al,
30 who compared sTMS and sham
TMS as an add-on treatment in a large population of
nondelusional MDD patients (N=70).Klein and cowork-
ers administered sTMS with a 9-cm round coil over the
RDLPFC at 1 Hz and 110% MT.The authors adminis-
tered two trains of 60 magnetic pulses each separated by
a 3-min interval.The TMS course was given daily for 10
days. The authors found that over 50% of the sTMS-
treated patients,but only 25% of the sham sTMS–treated
patients (ie, a significant difference) achieved a greater
than 50% decrease in the Hamilton rating scale for
depression (HRSD) score during the trial.
Studies with rTMS
Following the introduction of rTMS,an increasing num-
ber of studies using rTMS in the treatment of depression
are being published. George et al
31 published the first
study using rTMS in medication-resistant MDD.These
authors administered rTMS over the LDLPFC at 80%
MT and 20 Hz for 5 sessions. They described a 26%
Clinical research
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period merit particular discussion because of the impact
they have had on the field. Pascual Leone et al
32 pub-
lished the first sham TMS/rTMS comparison in
depressed psychotic patients.They tested the effects of
rTMS (real and sham) on 16 patients at various scalp
coil positions (LDLPFC, RDLPFC, and vertex). The
sham coil was held at a 45°.In a crossover study,Pascual
Leone et al administered one form of treatment daily for
5 days only and then observed the patients for 3 weeks.
Only stimulation of the LDLPFC led to significant
improvements in depression rating scales, and these
lasted for approximately 2 weeks. Although there has
been significant discussion regarding the methodology of
this study, there can be no argument about the impact
this publication has had on the field of rTMS.This land-
mark paper led to an explosion of studies in depression.
Shortly thereafter, George et al
33 published a double-
blind, single crossover, sham-controlled study of 12
patients with MDD,using the same parameters reported
in their previous study.They found a modest decrease of
26% in HRSD score with real rTMS over the 2 weeks of
the study.
Over the following years,a number of important studies
were published, some of them supporting the antide-
pressant effects of rTMS and others finding that there
was no difference from placebo or, at best, that there
were mild antidepressant effects.
32-43 During the year
2000, three relatively large studies (Grunhaus et al,
38
George et al,
37 and Pridmore et al
42) have reported sig-
nificant antidepressant effects for rTMS administered
over the LDLPFC. George et al conducted a parallel,
double-masked, sham-controlled study of rTMS over
the LDLPFC in patients with nondelusional MDD.
37
They studied 30 patients with MDD (21 unipolar and 9
bipolar),who were in the midst of an episode of illness.
Patients were assigned to either the active or sham
groups, and to either a 5-Hz or a 20-Hz group. Patients
received 10 rTMS treatments at 100% MT, with 16 000
stimulations given to both cells. The antidepressant
response was defined as a decrease of 50% or more in
the HRSD score. The proportion of patients respond-
ing in the active treatment group was significantly larger
(9 of 20) than that of the sham group (none of 10).How-
ever,there was no significant difference between the 5-
Hz and 20-Hz groups.George et al concluded that rTMS
significantly reduced depressive symptomatology.
A potential area of great impact of rTMS is in popula-
tions who are resistant to medications and are therefore
candidates for ECT. ECT is an accepted treatment for
medication-resistant MDD and also for MDD with delu-
sions.Rates of response to ECT are highest in the latter
group of patients.
44,45 However,ECT is a treatment with
significant limitations.Patients and their relatives often
object to it as a treatment because of a negative aura
that surrounds ECT. In addition, and especially in the
elderly or in medically ill individuals,ECT may be asso-
ciated with significant morbidity particularly in the car-
diovascular and respiratory systems. Finally, ECT often
induces reversible memory changes, but on occasion
may lead to permanent memory impairment.
45TMS,on
the other hand, is a procedure that is associated with
few side effects;it does not induce memory impairments
and does not require anesthesia.Thus,if TMS could lead
to sustained antidepressant responses in patients with
resistant or delusional MDD, then a significant thera-
peutic advance would be made. Zyss summarized this
possibility well when he stated that “deep brain stimu-
lation would be the end of ECT.”
46
We published the first study to compare the effects of
ECT and rTMS in patients referred for ECT.
38 In this
study, patients referred for ECT and suffering from
treatment-resistant MDD were randomly assigned to a
course of either ECT or rTMS (over the LDLPFC, at
90% MT, 20 treatment days, at 10 Hz, a total of 24 000
magnetic pulses). Response to treatment was analyzed
according to both changes in the HRSD and increases in
function as assessed by the global assessment of function
(GAF) scale. Patients responded equally well to both
treatments. However, when the response was analyzed
according to the presence or absence of psychosis,ECT
was clearly more effective in MDD patients with psy-
chosis.We concluded that rTMS, according to the para-
meters used, was as effective as ECT in nonpsychotic
MDD, but that ECT was clearly superior in psychotic
MDD.Dannon et al
47 have performed a follow-up study
on these patients and reported that relapse rates were
comparable in both groups.Relapse rates were approx-
imately 20% in the two groups. Thus, the beneficial
response seen with rTMS persisted for at least 6 months.
A replication study used the same rTMS and ECT
methodology, but added restrictions on medication use
(patients in both groups had to be free of psychotropic
medication with the exception of lorazepam up to 3 mg
per day) and required that raters be blind to treatment
modality (Grunhaus et al, unpublished data). In this
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rable results in nondelusional MDD.
The combined results of these two studies from our
group are presented in Table II.These results show that
ECT is the superior treatment when the whole sample is
considered;however,this holds true in delusional MDD,
but not in nondelusional MDD.In the latter group,ECT
and rTMS have comparable treatment outcomes.
Response to treatment was defined as a 50% or more
decrease in the HRSD score and a final GAF of 60
points or more.
Pridmore et al
42 also compared ECT and rTMS. They
studied 32 patients with MDD (it is not clear from their
publication whether delusional patients were excluded),
who had been resistant to a course of 4 weeks of antide-
pressant medication.They randomly assigned patients to
one of the two treatment groups. Raters were blind to
treatment group and response to treatment was assessed
with the HRSD.Treatments were provided as needed,or
up to a point when no further change was noted. rTMS
was administered at 100% MT, 20 Hz, for 2 s, 30 to 35
trains per day. The rate of remission was the same for
both groups, and the percentage of patients improving
was above 55% in both groups, but favored ECT in a
nonsignificant way.The authors concluded that rTMS had
useful antidepressant effects approaching those of ECT.
Janicak et al
43 randomly assigned 25 patients with a
major depression deemed clinically appropriate for ECT
to either rTMS (10-20 treatments, 10 Hz, 110% MT
applied to the LDLPFC for a total of 10 000 to
20 000 stimulations) or a course of bitemporal ECT 
(4-12 treatments). They found that the percentage
improvement on the baseline HDRS score did not sig-
nificantly differ between the two treatments (ie, 55%
for the rTMS group versus 64% for the ECT group
[NS]).With response defined as a 50% reduction from
baseline and a final score <8 on the HDRS,there was no
significant difference between the two groups. These
authors concluded that bitemporal ECT and rTMS have
similar antidepressant effects.
In an attempt to conceptualize the state of the art of
TMS in MDD,Sackeim
48 concluded that both sTMS and
rTMS (to the left DLPFC) exert “important antide-
pressant effects over and beyond those of placebo con-
tributions”;nonetheless he questioned whether enough
evidence has accumulated to suggest clinical utility for
TMS in MDD.He proposed two directions for research
to clarify this question: (i) to attempt to identify indi-
vidual differences in patients that are predictive of
response; and (ii) to optimize the parameters for TMS
delivery.
There is no doubt that the studies published over the
past 2 years are offering increasing evidence of the effi-
cacy of rTMS, especially in nondelusional MDD. Inter-
estingly, several studies have found that rTMS can be
as effective as ECT. No study has been published that
simultaneously compares the clinical efficacy and the
cognitive impact of either rTMS or ECT.However,from
the evidence published so far it appears that rTMS is
devoid of negative effects on cognition and memory,
49
while ECT has marked, and probably also prolonged,
effects on these functions.
50-52 On the basis of the studies
that we have reviewed,it appears imperative to include
rTMS in the armamentarium of treatments offered to
patients with severe depression, especially if ECT is
being considered.
Effects of TMS 
on cortical excitability
How magnetic stimulation of discreet areas of the pre-
frontal cortex leads to antidepressant effect is a very
interesting and puzzling question.The number of stud-
ies in laboratory animals looking at the mechanisms of
ECT actions has been steadily increasing and the reader
is referred to recent publications that have dealt com-
prehensively with this topic.
53-55 In this publication, we
will limit ourselves to a review of the human studies
dealing with cortical excitability as a correlate of TMS
actions in humans.
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Table II. Response to treatment. ECT, electroconvulsive therapy; rTMS, repetitive transcranial magnetic stimulation.
ECT group (N=40) rTMS group (N=40) P
Responders Nonresponders Responders Nonresponders
Whole sample 28 12 19 22 0.03
Psychotic 9 5 3 10 0.03
Nonpsychotic 19 7 16 12 NSCortical excitability in MDD
Measuring cortical excitability can provide an assess-
ment of the neurophysiological state of the brain. It is
likely that the therapeutic effects of TMS are mediated
by TMS-induced changes in the metabolism and
excitability of the stimulated cortex.
56
Cortical excitability in major depression can be assessed
at baseline and following TMS treatments. The former
provides information on the underlying state of the
motor cortex in depression, while the latter reflects the
effects of the treatment. Although in depression TMS
is administered over the prefrontal cortex, it has been
shown that LDLPFC stimulation has an impact on
motor cortex excitability. Rollnick et al
57 have shown
that rTMS given at 5 Hz and 90% MT over the
LDLPFC led to decreases in MEP areas obtained with
single-pulse TMS stimulations over the motor cortex.
The authors speculated that this inhibitory effect was
due to either an antagonism between the frontal and
parietal lobes (prefrontal motor connections) or one
that follows the activation of subcortical projections.
A number of methods can be used to assess cortical
excitability.
13,56 In major depression, reports have
included measurement of MT, changes in MEP ampli-
tude with the input-output curve, postexercise facilita-
tion of MEP, paired-pulse stimulation, and effects on
the poststimulation EMG silent period. Table III pre-
sents definitions of the various cortical excitability tests
that have been explored in major depression.
Motor threshold
Triggs et al
58 treated 10 MDD patients with rTMS (20 Hz,
at 80% MT,2000 stimulations per day for 10 days,over the
LDLPFC) and reported a significant positive correlation
between decreases in MT and HRSD scores with treat-
ment. The changes in MT reported by Triggs et al were
small but significant.In a study from our group (Dolberg
et al,unpublished data),changes in MT were explored in
a group of 46 patients with MDD treated with rTMS and
in normal controls. No differences were identified in MT
between patients and controls. In addition, MT did not
change with treatment and showed no association with
severity, age, or the presence of psychosis. It is possible
that the differences observed in our study and those
reported by Triggs et al were related to differences in the
methods of determining MT. Triggs et al defined MT as
100-µV MEP deflections in the EMG, whereas we used
the more widely accepted cutoff of 50 µV.
Postexercise facilitation
It is well established that muscular activation increases
the size of the MEPs during TMS.Samii et al
59 and Sha-
jahan et al
60,61 explored this paradigm in patients with
acute depression,in recovered depressed patients,and in
normal controls. They found that patients in the acute
stage of the illness had significantly less postexercise
facilitation than normal controls or recovered patients.
They speculated that this lack of facilitation in depressed
patients is due to decreased cortical excitability (which
may be secondary to increased inhibitory outflow from
interneurons), and that the normalization seen with
recovery reflects the normalization of underlying neuro-
biological processes.
Silent period
A variable period of EMG absence follows an MEP.
This period is referred to as the silent period and it is
believed to be, at least in part, secondary to increased
inhibitory forces in the motor cortex.
13 Steele et al
62
looked at the post-TMS silent period in patients with
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Table III. Definitions of tests used to assess cortical excitability in major
depression. TMS, transcranial magnetic stimulation; MEP, motor
evoked potential.
Test Definition
Motor threshold Minimal amount of TMS intensity
that induces a deflection of 50 µV
in electromyographic recordings
(MEPs) in 5 out of 10 trials
Postexercise facilitation Increase in MEP size observed after
exercise
Silent period Variable period of electromyo-
graphic silence observed after the
occurrence of an MEP
Paired-pulse stimulation Modifications of MEP amplitude by
prestimulation challenges 
administered at variable intervals
Input-output curve Averaged MEP area following a
series of TMS stimulations or 
modifications of MEP amplitude
induced by gradients of TMS
stimulationsdepression and compared it with that of normal con-
trols. They found that depressed patients had longer
post-TMS silent periods than normal controls.They con-
cluded that their findings were indirect evidence for the
presence of state-dependent increased inhibitory mech-
anisms in the motor cortex, and possibly other areas of
the brain, in depression. It has not been reported
whether recovery from depression was associated with a
normalization of the silent period.
Paired-pulse stimulation
Paired-pulse stimulation of the motor cortex is consid-
ered today to be the gold standard of motor cortex
excitability.
13,56,63 The paired TMS stimulations are given
with short intervals between them (interstimulus inter-
vals [ISIs]). The effects depend on the intensity of the
conditioning and test stimulus,and on the ISI.Short ISIs
are believed to reveal inhibitory cortical mechanisms,
whereas long ISI are thought to reveal excitatory corti-
cal mechanisms.Paired-pulse stimulation has been stud-
ied extensively in neurology, but much less in depres-
sion. Maeda et al
63 studied eight subjects with major
depression with the paired-pulse paradigm and com-
pared their responses with that of normal controls.They
found significant interhemispheric differences in MT
and in the paired-pulse response, both showing lower
excitability in the left hemisphere.
Input-output curve
The input-output curve is obtained either by stimulating
with progressively increasing TMS intensities or by mea-
suring MEP size following a set number of suprathresh-
old TMS stimulations to the motor cortex.Input-output
curves can be obtained during a course of TMS without
major changes to the treatment protocol. In a sample
of 16 patients with major depresssion, we tested the
hypothesis (Grunhaus et al,unpublished data) that exci-
tatory responses to rTMS (10 Hz, 90% MT, LDLPFC,
1200 pulses per treatment) would be associated with
positive clinical response.We did not identify an associ-
ation between the input-output curve and response to
rTMS.We did,however,find a clear age effect,in which
older patients had overall lower MEP size responses.
This association suggests that older individuals may
require more intense TMS stimulations to respond to
rTMS.
In summary,cortical excitability can be readily studied in
patients with major depression. The studies published
so far suggest that decreased cortical excitability, and
possible left to right differences, predominate in major
depression. The negative correlation between age and
MEP response reported by our group provides some
indication that higher TMS intensities are needed for
response in older patients. Future studies need to look
into possible associations between cortical excitability
and clinical variables like psychosis, response to treat-
ment,and gender.
Discussion
The idea of using TMS as an antidepressant treatment is
less than 10 years old. It is remarkable that in this short
period of time the technique of TMS has developed so
impressively,particularly in view of the large number of
parameters that may have an impact on how TMS affects
the brain.Most,but not all,of the publications exploring
the antidepressant effects of TMS have found at least a
moderate degree of positive results.Of particular interest
are those studies that have found TMS comparable to
ECT in the treatment of MDD.Follow-up of small sam-
ples following TMS suggests that the therapeutic effects
of TMS extend for as long as those of ECT.
There is little doubt that TMS is in the process of
becoming a much more complex technical procedure.
Post and Speer
64 have described nearly 10 parameters
that need to be explored in order to optimize the anti-
depressant effects of TMS.The technique of neuronavi-
gation based on MRI and stereotactic positioning of the
coil
17,18 will improve our ability to reliably replicate the
coil positioning over the selected cortical areas. Calcu-
lations of TMS intensity based on scalp-to-cortex dis-
tance
14,15 will require precise methodology combining
MRI and clinical psychiatry. Finally, imaging methods
such as single photon emission computed tomography
(SPECT),functional MRI (fMRI),or positron emission
tomography (PET) may provide evidence for the pres-
ence of hyper- or hypometabolic states in major depres-
sion.Speer et al
65 have shown that optimization of TMS
parameters in the treatment of depression may depend
on precise knowledge of the underlying physiological
state of the brain.
Future administration of TMS will most probably
involve more extensive stimulation paradigms and
longer treatment periods.It would be invaluable to have
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bedside methods for monitoring the effects of the mag-
netic trains on the cortex. Cortical excitability studies
show some promise in providing this kind of informa-
tion. However, the prefrontal cortex, the area of the
brain most commonly stimulated in major depression,
cannot be assessed with the usual cortical excitability
probes. A neurophysiological method that is yet to be
tested extensively during TMS is quantitative elec-
troencephalography (qEEG). Preliminary studies sug-
gest that the effects of TMS can indeed be monitored
with qEEG.
66,67
The final and most relevant question continues to be
whether TMS is ready to be offered as a treatment to
patients with major depression. The evidence accumu-
lated during the recent past strongly supports a positive
answer to this question.❑
La estimulación magnética transcraneal:
una nueva herramienta en la lucha contra
la depresión
Desde su introducción al campo clínico en 1985, la
estimulación magnética transcraneal (EMT) se ha
desarrollado rápidamente como una herramien-
ta para explorar la función del sistema nervioso
central tanto en el sujeto sano como en el enfer-
mo. Los efectos antidepresivos de la EMT se obser-
varon inicialmente en 1993. Desde esa fecha se ha
acumulado un cuerpo sólido de evidencias que
sugiere los efectos antidepresivos para la EMT
lenta (EMT l) y la EMT repetitiva (EMT r). Esta revi-
sión está dividida en cuatro partes. La primera
parte se orienta hacia los conceptos básicos que
rigen la EMT y en la segunda se discuten los pará-
metros técnicos que participan en la administra-
ción de la EMT. El conocimiento de estos paráme-
tros es necesario para entender cómo se
administra la EMT y cómo la manipulación de la
técnica afecta los resultados obtenidos. En la ter-
cera parte se revisan los estudios más relevantes
de los efectos antidepresivos de la EMT l y de la
EMT r  publicados hasta la fecha. Finalmente se
discute la excitabilidad cortical y cómo la com-
prensión de esta función neurofisiológica básica
de las neuronas corticales se puede usar para
monitorear los efectos de la EMT. En la discusión
se concluye que ha llegado el tiempo para que la
EMT sea ofrecida a los pacientes depresivos como
un tratamiento.
La stimulation magnétique
transcrânienne : un nouvel outil dans 
la lutte contre la dépression
Depuis son introduction en clinique en 1985, la
stimulation magnétique transcrânienne (SMT)
s’est rapidement développée en outil d’explora-
tion de la fonction du système nerveux central
malade ou sain. Les effets antidépresseurs de la
SMT furent reconnus dès 1993. Depuis lors, les
effets antidépresseurs de la SMT lente (SMTl)
comme de la SMT répétitive (SMTr) ont été soli-
dement confirmés. Cette mise au point est divi-
sée en quatre parties. Après avoir abordé les
grands concepts à la base de la SMT, nous pas-
sons en revue les paramètres techniques condi-
tionnant l'administration de la SMT. La connais-
sance de ces paramètres est nécessaire pour com-
prendre l’administration de la SMT et comment
le mode d'utilisation de cette dernière influe sur
les résultats obtenus. En troisième partie, cet
article traite des études les plus pertinentes sur
les effets antidépresseurs de la SMTl et de la
SMTr publiées jusqu’à maintenant. La dernière
partie, enfin, examine l’excitabilité corticale et
comment la compréhension de cette fonction
neurophysiologique de base des neurones corti-
caux peut être utilisée pour contrôler les effets
de la SMT. La conclusion qui s'impose est qu’il est
grand temps de proposer la SMT dans le traite-
ment des patients déprimés. Clinical research
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